Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung

Cancer Biomarkers

Volumn 11, Issue 2-3, 2012, Pages 123-128

  Bondgaard, Anna Louise Reinert Ørsum ^a,b   Poulsen, Thomas Tuxen ^a   Poulsen, Hans Skovgaard ^a   Skov, Birgit Guldhammer ^b  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

BMI1; carcinoids; EZH2; Ki67; large cell neuroendocrine carcinoma; Neuroendocrine tumors of the lung; small cell lung cancer

Indexed keywords

BMI1 PROTEIN; KI 67 ANTIGEN; PARAFFIN; TRANSCRIPTION FACTOR EZH2;

ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL CARCINOID; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARCINOID; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL PREDICTION; TYPICAL CARCINOID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84867569866     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0269     Document Type: Article

References (29)

1. B. Gustafsson, M. Kidd et al., Bronchopulmonary neuroendocrine tumors, Cancer 113 (2008), 5-21. (Pubitemid 351976381)
2. M.T. Siddiqui, Pulmonary neuroendocrine neoplasm: A review, Diagn Cytopath 38 (2010), 607-17.
3. W.D. Travis WD, E. Brambilla et al., Pathology and Genetics: Tumors of the lung, pleura, thymus, heart, World Health Organization Classification of Tumours, IARCPress (2004).
4. K.K. Ciombor, C.M. Rocha Lima, Management of small cell lung cancer, Curr Treat Options Oncol 7 (2006), 59-68. (Pubitemid 43141433)
5. O. Rena, P.L. Filosso et al., Broncopulmonary carcinoid tumors, Minerva Chir 57 (2002), 403-23.
6. B.G. Skov, B. Holm et al., ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival, Jr Thorac Oncol 5 (2010), 453-59.
7. H. Santos-Rosa, C. Caldas, Chromatin modifier enzymes, the histone code and cancer, Eur J Cancer 41 (2005), 2381-40.
8. A.V. Ougolkov, V.N. Bilim et al., Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2, Clin Cancer Res 14 (2008), 6790-96.
9. E.Viŕe E, C. Brenner et al., The Polycomb group protein EZH2 directly controls in DNA methylation, Nature 439 (2006), 871-74. (Pubitemid 43255707)
10. J.A. Simon, C.A. Lange, Roles of EZH2 histone methyltransferase in cancer epigenetics, Mutat Res 647 (2008), 21-29.
11. A.H. Lund, M. van Lohuizen, Polycomb complexes and silencing mechanisms, Curr Opin Cell Biol 16 (2004), 239-46. (Pubitemid 38610403)
12. S.S. Levine, I.F. King et al., Division of labor in the polycomb group repression, Trends Biochem Sci 29 (2004), 478-85. (Pubitemid 39158871)
13. L. Ringrose, R. Paro, Epigenetic regulation of the cellular memory by the polycomb and trithorax group proteins, Annu Rev Genet 38 (2004), 413-43. (Pubitemid 40013734)
14. A. Sparmann, M. van Lohuizen, Polycomb silencers control cell fate, development and cancer, Nat Rev Cancer 6 (2006), 846-56. (Pubitemid 44629896)
15. F.M. Raaphorst, Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors, Hum Mol Genet 14 (2005), R93-R100. (Pubitemid 40542625)
16. A.M. Pietersen, H.M. Horlings et al., EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer, Breast Cancer Res 10 (2008), R109.
17. R. Cao, L.Wang et al., Role of histone H3 lysine 27 methylation in polycomb group silencing, Science 298 (2002), 1039-43. (Pubitemid 35247314)
18. S.W. Lowe, C.J. Sherr, Tumor suppressor by Ink4a-Arf: progress and puzzles, Curr Opin Genet Dev 13 (2003), 77-83. (Pubitemid 36143931)
19. D. O'Carroll, S. Erhardt et al., The polycomb-group gene EZH2 is required for early mouse development, Mol Cell Biol 21 (2001), 4330-36. (Pubitemid 32565314)
20. G.V. Glinsky, O. Berezovska et al., Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer, J Clin Invest 115 (2005), 1503-21. (Pubitemid 40814659)
21. T.T. Poulsen, N. Pedersen et al., A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells, Cancer Gene Ther 15 (2008), 563-75.
22. J.J. Findeis-Hosey, J. Huang et al., High grade neuroendocrine carcinomas of the lung higly express enhancer of zeste homolog 2, but carcinoids do not, Hum Pathol 42 (2011), 867-72.
23. L.K. Koch, H. Zhou et al., Stem cell marker expression in small cell lung carcinoma and developing lung tissue, Hum Pathol 39 (2008), 1597-1605.
24. B.G. Skov,M.Krasnik, S. Lantuejoul et al., Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival, J Thorac Oncol 12 (2008), 1410-5.
25. C.F. Mountain, Revisions in the International System for Staging Lung Cancer, Chest 111 (1997), 1710-17. (Pubitemid 27260107)
26. I.M. Bachmann, O.J. Halvorsen, K. Collett et al., EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast, J Clin Oncol 24 (2006), 268-73. (Pubitemid 46622055)
27. A. Chase, N.C. Cross, Aberrations of EZH2 in Cancer, Clin Cancer Res 17 (2011), 1-6.
28. J.C. Steele, E.E. Torr et al., The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens, Br J Cancer 95 (2006), 1202-211. (Pubitemid 44658484)
29. G.V. Glinsky, "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management, J Clin Oncol 26 (2008), 2846-853.